Evidence map›Paper›PMID 37592363›Full record

ArticlePediatric blood & cancer2023

Assessment of proxy-reported responses as predictors of motor and sensory peripheral neuropathy in children with B-lymphoblastic leukemia.

Rozalyn L Rodwin, Natalie J DelRocco, Emily Hibbitts, Meenakshi Devidas, Moira K Whitley, Caroline E Mohrmann, Reuven J Schore, Elizabeth Raetz, Naomi J Winick, Stephen P Hunger and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 2 countries.

Rozalyn L RodwinDepartment of Pediatrics, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-5243-3284
Natalie J DelRoccoDepartment of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, Florida, USA.
Emily HibbittsDepartment of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, Florida, USA.
Meenakshi DevidasDepartment of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Moira K WhitleyDepartment of Pediatrics, Yale School of Medicine, New Haven, Connecticut, USA.
Caroline E MohrmannDepartment of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, Missouri, USA.ORCID 0000-0002-1198-0433
Reuven J SchoreCenter of Cancer and Blood Disorders, Children's National Health System, Washington, District of Columbia, USA.ORCID 0000-0002-1582-2168
Elizabeth RaetzDepartment of Pediatrics, NYU Langone Health, New York, New York, USA.ORCID 0000-0002-8547-1658
Naomi J WinickDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-6636-3870
Stephen P HungerDepartment of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Mignon L LohDivision of Pediatric Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy, Seattle Children's Hospital and the Ben Towne Center for Childhood Cancer Research, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-4099-4700
Marilyn J HockenberryDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Xiaomei MaYale Cancer Center, New Haven, Connecticut, USA.
Anne L AngiolilloCenter of Cancer and Blood Disorders, Children's National Health System, Washington, District of Columbia, USA.
Kirsten K NessDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-2084-1507
John A KairallaDepartment of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, Florida, USA.
Nina S Kadan-LottickCancer Prevention and Control Program, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA.
University of Florida Health · USChildren's National · USSt. Jude Children's Research Hospital · USYale Cancer Center · USChildren's Hospital of Philadelphia · USDuke University · USGeorgetown University Medical Center · USNYU Langone Health · USSeattle Children's Hospital · USSt. Louis Children's Hospital · USThe University of Texas Southwestern Medical Center · USYale University · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
Towards a preventive cancer vaccine for children with constitutional mismatch repair deficiencyUG1CA189955 · NCI · PUBLIC HEALTH INSTITUTE · PI BRAD H POLLOCK, Michael E. Roth · 2014 to 2026
$62.5M
Community Clinical Oncology Program Research BaseU10CA095861 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI POLLOCK, BRAD H · 2002 to 2013
$19.5M
The Yale Cancer Prevention and Control Training ProgramT32CA250803 · NCI · YALE UNIVERSITY · PI Melinda L Irwin, Xiaomei Ma · 2020 to 2026
$2.3M
NCATS NIH HHS UL1 TR001863NCI NIH HHS T32 CA250803NCI NIH HHS U10 CA095861NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS UG1 CA189955
6 · The paper itself

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN), a common condition in children with acute lymphoblastic leukemia, can be challenging to diagnose. Using data from Children's Oncology Group AALL0932 physical function study, we sought to determine if parent/guardian proxy-reported responses from the Pediatric Outcomes Data Collection Instrument could identify children with motor or sensory CIPN diagnosed by physical/occupational therapists (PT/OT). Four variables moderately discriminated between children with and without motor CIPN (c-index 0.76, 95% confidence interval [CI]: 0.64-0.84), but sensory and optimism-corrected models had weak discrimination (c-index sensory models 0.65, 95% CI: 0.54-0.74). New proxy-report measures are needed to identify children with PT/OT diagnosed CIPN.

Indexed as

Antineoplastic AgentsPeripheral Nervous System DiseasesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaChildHumansPhysical ExaminationQuality of LifeAntineoplastic Agentschemotherapy-induced peripheral neuropathymotor neuropathypediatric acute lymphoblastic leukemiaproxy-reported surveyssensory neuropathy

Identifiers

PMID37592363
PMCPMC10552080
OpenAlexW4385969110

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.